ES2666397T3 - Activación de CD89 en terapia - Google Patents

Activación de CD89 en terapia Download PDF

Info

Publication number
ES2666397T3
ES2666397T3 ES11794757.2T ES11794757T ES2666397T3 ES 2666397 T3 ES2666397 T3 ES 2666397T3 ES 11794757 T ES11794757 T ES 11794757T ES 2666397 T3 ES2666397 T3 ES 2666397T3
Authority
ES
Spain
Prior art keywords
therapy
activation
molecule
activating molecule
activating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11794757.2T
Other languages
English (en)
Inventor
Stephan von Gunten
Marc Wehrli
Adrian ZÜRCHER
Sylvia Miescher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
CSL Behring AG
Original Assignee
Universitaet Bern
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Bern, CSL Behring AG filed Critical Universitaet Bern
Application granted granted Critical
Publication of ES2666397T3 publication Critical patent/ES2666397T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una molécula activadora de CD89 para su uso en el tratamiento de una afección inflamatoria o un trastorno autoinmunitario, mediante la inducción de la apoptosis en neutrófilos, donde la molécula activadora de CD89 es una molécula que comprende Fc alfa, que se administra como una solución estéril.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES11794757.2T 2010-12-14 2011-12-14 Activación de CD89 en terapia Active ES2666397T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10194942 2010-12-14
EP10194942A EP2465536A1 (en) 2010-12-14 2010-12-14 CD89 activation in therapy
PCT/EP2011/072711 WO2012080306A1 (en) 2010-12-14 2011-12-14 Cd89 activation in therapy

Publications (1)

Publication Number Publication Date
ES2666397T3 true ES2666397T3 (es) 2018-05-04

Family

ID=43952841

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11794757.2T Active ES2666397T3 (es) 2010-12-14 2011-12-14 Activación de CD89 en terapia

Country Status (16)

Country Link
US (2) US9522184B2 (es)
EP (2) EP2465536A1 (es)
JP (1) JP6245986B2 (es)
KR (1) KR101946231B1 (es)
CN (1) CN103313728B (es)
AU (1) AU2011343392B2 (es)
BR (1) BR112013014669A2 (es)
CA (1) CA2821296A1 (es)
DK (1) DK2651440T3 (es)
ES (1) ES2666397T3 (es)
IL (1) IL226805B (es)
MX (1) MX355394B (es)
NZ (1) NZ610891A (es)
RU (1) RU2640082C2 (es)
SG (1) SG190917A1 (es)
WO (1) WO2012080306A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2465536A1 (en) * 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
MX360245B (es) 2012-03-09 2018-10-26 Csl Behring Ag Composiciones que comprenden inmunoglobulinas de tipo secretor.
US9458230B2 (en) 2013-01-04 2016-10-04 Wisconsin Alumni Research Foundation Secretory IGA compositions, methods of making and methods of use thereof
US9468674B2 (en) * 2013-09-24 2016-10-18 Wisconsin Alumni Research Foundation Methods of use of secretory IgA
CN107428840A (zh) * 2015-03-25 2017-12-01 弗劳恩霍夫应用研究促进协会 抗cd89细胞毒素的复合物
BR112020005742A2 (pt) 2017-09-21 2020-10-13 Umc Utrecht Holding B.V. anticorpo anti-gd2 para o tratamento de neuroblastoma
CN114096559B (zh) 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
US20220133761A1 (en) * 2020-11-04 2022-05-05 Washington State University Neutrophil apoptosis induced by nanoparticles for treating inflammatory diseases
CN116731161A (zh) * 2021-09-18 2023-09-12 南开大学 工程化IgG和IgA嵌合的“四叶草型X抗体”

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004081A1 (en) 1993-07-30 1995-02-09 Oravax, Inc. MONOCLONAL IgA ANTIBODY AGAINST RESPIRATORY SYNCYTIAL VIRUS
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6300104B1 (en) * 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
NZ527977A (en) * 2001-02-12 2005-10-28 Medarex Inc Human monoclonal antibodies to FC alpha receptor (CD89)
US6932967B2 (en) * 2001-03-22 2005-08-23 Michael R. Simon Human medical treatment by aerosol inhalation of immunoglobulin A
US20060165675A1 (en) 2002-08-02 2006-07-27 Richman-Eisenstat Janice Beth Modulation of mesenchymal cells via iga-receptors
WO2005047337A1 (en) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
EP2465536A1 (en) * 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy

Also Published As

Publication number Publication date
MX2013006589A (es) 2014-02-06
IL226805B (en) 2019-10-31
BR112013014669A2 (pt) 2016-11-29
AU2011343392B2 (en) 2017-01-05
WO2012080306A1 (en) 2012-06-21
EP2465536A1 (en) 2012-06-20
SG190917A1 (en) 2013-07-31
CA2821296A1 (en) 2012-06-21
RU2013132220A (ru) 2015-01-20
JP6245986B2 (ja) 2017-12-13
US9522184B2 (en) 2016-12-20
KR20140048077A (ko) 2014-04-23
RU2640082C2 (ru) 2017-12-26
EP2651440B1 (en) 2018-01-24
DK2651440T3 (en) 2018-05-07
EP2651440A1 (en) 2013-10-23
AU2011343392A1 (en) 2013-05-02
CN103313728A (zh) 2013-09-18
NZ610891A (en) 2015-05-29
MX355394B (es) 2018-04-18
US20170166640A1 (en) 2017-06-15
CN103313728B (zh) 2016-11-09
JP2014502962A (ja) 2014-02-06
US20130302345A1 (en) 2013-11-14
KR101946231B1 (ko) 2019-02-12

Similar Documents

Publication Publication Date Title
ECSP24031979A (es) Compuestos terapéuticamente activos y sus métodos de uso
CL2012002037A1 (es) Uso de agonista doble del glucagon-glp-1 como agente inotropico en el tratamiento de la cardiopatía o la disfuncion cardiaca
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
GT201300215A (es) Inhibidores de glucosilceramida sintasa
NI201100075A (es) Agonistas del receptor gpr120 de arilo y usos de los mismos.
CR20110622A (es) Conjunto de aguja para dispositivo para biopsias
MX2021001425A (es) Compuestos terapeuticos activos y sus usos.
BR112012011086A2 (pt) uso de betanecol para o tratamento de xerostomia
CL2009000048A1 (es) Uso de compuestos derivados de triterpenoides en el tratamiento de insuficiencia renal, y enfermedades asociadas tales como: nefropatías, resistencia a la insulina, diabetes, patologías vasculares, entre otras.
CR20150200A (es) Derivados de exendina-4 como agonistas duales de glp1/glucacón
ECSP11011149A (es) Agonistas del receptor gpr120 y usos de los mismos
BR112012002081B8 (pt) Dispositivo de tratamento bucal
AR065589A1 (es) Prediccion de respuesta a un inhibidor her
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
GT200900209A (es) Compuestos triciclos y su uso como moduladores del receptor de glucocorticosteroides
ES2528366T3 (es) Citicolina para el tratamiento del glaucoma
CR20140400A (es) Terapia combinada para el tratamiento del cancer de ovario
CL2017002156A1 (es) Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
CL2016001578A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c.
NI201000173A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre.
AR091353A1 (es) Dispositivo de suministro de farmacos
ES2664171T3 (es) Aditivo retardador del fraguado y plastificante para el hormigón